January, 2024

Remove drug-pricing-controlled-substances
article thumbnail

Pharma in Brief’s 2023 Year in Review and Trends for 2024

Pharma in Brief

Expected highlights for 2024 include a final PTA regime, more details on PMPRB drug pricing guidelines and national pharmacare, and fall-out from the US mass drug importation program targeting Canadian medicines. The PMPRB reviews the prices of patented medicines to ensure that they are not sold at “excessive” prices.